חדשות למשקיעים ב- IRON: אם סבלתם הפסדים ב- Disc Medicine, Inc (נאסד"ק: IRON), אתם מוזמנים ליצור קשר עם משרד רוזן עורכי הדין בנוגע לזכויותיכם

Rosen Law Firm is investigating potential securities fraud claims against Disc Medicine, Inc. (NASDAQ: IRON) following the FDA's rejection of the company's bitopertin drug application on February 13, 2026. The rejection, citing uncertainties requiring additional evidence, caused the stock to plummet 22%. Investors who suffered losses are encouraged to join a class action lawsuit.